Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype

• Published in: Journal of thrombosis and haemostasis 2020-06, Vol.18 (6), p.1330-1334
• Main Authors: Bovet, Julien, Hurják, Boglárka, De Maistre, Emmanuel, Katona, Éva, Pénzes, Krisztina, Muszbek, László
• Format: Article
• Language: English
• Subjects: Aged; Autoantibodies; autoimmune disease; blood coagulation; Calcium; Coagulation factors; Embolism; Enzyme-linked immunosorbent assay; factor XIII; Factor XIII - genetics; factor XIII deficiency; Factor XIII Deficiency - diagnosis; Factor XIII Deficiency - drug therapy; Factor XIIIa; Female; Fibrin; Hematoma; Hemorrhage; hemorrhagic disorder; Humans; Immunoglobulin G; Laboratories; Patients; Phenotype; Phenotypes; Thrombosis; Western blotting
• ISSN: 1538-7933; 1538-7836; 1538-7836
• DOI: 10.1111/jth.14811

Hemorrhagic diathesis due to anti‐factor XIII (FXIII) autoantibody is a rare but severe disorder. Challenges of the diagnosis and treatment is demonstrated by the case of a 67‐year‐old female without previous bleeding history, who suffered a huge muscular hematoma. Without blank subtraction 18% plasma FXIII activity was measured; however, after correction for blank the activity was below the limit of detection and the lack of fibrin cross‐linking in the patient's plasma confirmed the latter result. FXIII‐A2 antigen was not detectable by enzyme‐linked immunosorbent assay (ELISA); however, it was well detected by western blotting. The autoantibody showed high affinity toward FXIII‐A2. Its considerable inhibitory activity was demonstrated by high titer in Bethesda units and the low immunoglobulin G concentration required for inhibition. The main biochemical effect was the inhibition of Ca2+‐induced activation. Eradication therapy was only partially successful. Four months after the last hemorrhagic event the patient suffered deep vein thrombosis complicated by pulmonary embolism.